FDA advisory panelists describe decision to recommend approval of "female Viagra"

Three panelists from the FDA's advisory panel offered their views on the panel's decision to recommend approval of Sprout Pharmaceuticals' flibanserin

Five things for pharma marketers to know: Tuesday, July 7

Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher

The 2015 Agency Issue

Agency business again appears to be up for a healthy cross-section of companies this year

Welcome to MM&M's 2015 Agency Issue!
Here you'll find original profiles, findings of our annual business barometer, all 100 North American healthcare marketing and advertising firms ranked by 2014 revenue, an infographic of the agency universe, a Q&A with holding-company level health execs, and the Agency A to Z definitive annual directory.

Latest

Insurance trade group says new HCV drugs could cost California billions

An analysis by a state insurance trade group forecast that paying for new HCV treatments could cost taxpayers billions of dollars.

Curious if you're a finalist in the MM&M Awards? Find out now

Curious if you're a finalist in the MM&M Awards? Find out now

The finalists in each of the 32 categories for this year's MM&M Awards are revealed here.

Vertex's Orkambi nabs FDA approval but may face payer backlash

Vertex's Orkambi nabs FDA approval but may face payer backlash

The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.

Fit4D expands diabetes program with Healthfirst

The health insurer will offer Fit4D's diabetes coaching program to its members after testing the program during a pilot last year.

Steady Leadership, Focus on Infrastructure Expected from the FDA's "Acting" Head

Steady Leadership, Focus on Infrastructure Expected from the FDA's "Acting" Head

Dr. Stephen Ostroff took over as the FDA's acting commissioner when Dr. Margaret Hamburg stepped down in March.

Five things for pharma marketers to know: Monday, July 6

Five things for pharma marketers to know: Monday, July 6

Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company

Five things for pharma marketers to know: Thursday, July 2

Five things for pharma marketers to know: Thursday, July 2

Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs

Sermo expands to Canada in global expansion

Sermo expands to Canada in global expansion

The social networking site for doctors also plans to expand to its first Spanish-speaking country next month.

Pharmacy groups urge consistent naming of biosimilars

Pharmacy groups urge consistent naming of biosimilars

The health insurance industry's trade association, along with other organizations, sent a letter to the FDA arguing that different names could lead to prescriber confusion and medication errors.

Five things for pharma marketers to know: Wednesday, July 1

Five things for pharma marketers to know: Wednesday, July 1

Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME

Five things for pharma marketers to know: Tuesday, June 30

Five things for pharma marketers to know: Tuesday, June 30

Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol

Manufacturers pay $6.5 billion to healthcare providers in 2014

Manufacturers pay $6.5 billion to healthcare providers in 2014

The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.

Havas Health acquires London-based PR shop

Havas Health acquires London-based PR shop

Havas Health adds PR agency Just:: Health Communications in bid to expand its global footprint.

Five things for pharma marketers to know: Monday, June 29

Five things for pharma marketers to know: Monday, June 29

A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again

Agency Spotlight


Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.